AbbVie Inc. ABBV 70.65
Health Care · NYSE · Data as of 2026-08-06
AbbVie Inc. (ABBV) has delivered +10.9% annualized revenue growth, -1.9% earnings growth, and +14.2% dividend growth over 10 years of data. Ranked #245 of 1968 stocks overall and #24 of 260 in the Health Care sector by Steady Score.
About AbbVie Inc.
Company Overview
AbbVie develops and sells prescription medicines across immunology, oncology, neuroscience, eye care and aesthetics. Its products treat autoimmune diseases, cancers, neurological conditions and vision disorders, while the aesthetics portfolio includes Botox Cosmetic and dermal fillers. Physicians, hospitals, pharmacies and patients use these therapies worldwide, with payment coming through private insurers, government programs and direct consumer spending in aesthetics.
Read more
Business Model & Revenue
Revenue comes from branded medicines and medical-aesthetic products protected by patents, regulatory exclusivity and clinical data. Prescription volume, approved indications, pricing and reimbursement determine sales. Patents expire, exposing products to generic or biosimilar competition, so AbbVie invests in internal research, licensing and acquisitions to renew the portfolio. Wholesalers distribute many medicines, while aesthetics uses physician-focused commercial channels.
Key Facts & Market Position
AbbVie's immunology franchise is transitioning from Humira toward newer therapies such as Skyrizi and Rinvoq, making successful portfolio replacement especially important. The Allergan acquisition added neuroscience, eye care and aesthetics and increased diversification. Clinical safety, regulatory approvals, payer access and manufacturing quality determine whether large development investments become durable products.